The Potential to Combine KIT and CTLA-4 Blockade in Patients With GIST

September 10, 2014
William D. Tap, MD

William D. Tap, MD, discusses the potential to combine KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.

Clinical Pearls

William D. Tap, MD, Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential to combine KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.

  • When GIST respond to imatinib, an important immune-mediated response occurs. Research has shown that an immune response is often responsible for the development of resistance to drugs such as imatinib.
  • If a checkpoint inhibitor is given after a TKI, an improvement in the immune response is seen.
  • As drug resistance makes GIST difficult to treat, the hope is that combining drugs such as dastinib and ipilimumab may be a new option for patients.